Koyo Sciences
Brookline, US · Founded 2025 · Delaware corporation
Koyo Sciences is a biotechnology company developing an oral human growth hormone therapy derived from algae as a non-invasive alternative to injectable treatments for Growth Hormone Deficiency. Its research spans biology, chemistry, and data with a focus on health and sustainability.
Founders & leadership
DD
David DoveExecutive
JD
Jonathan Daniel ReisExecutive
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 1 round · 2025
▶$1.3MraisedJun 2025 · 2 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJun 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David DoveExecutive Officer, Director
- Jonathan Daniel ReisExecutive Officer, Director
- Offering amount
- $20.4M
- Amount sold
- $1.3M
- Minimum investment
- $111K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Koyo Sciences do?
- Koyo Sciences is a biotechnology company developing an oral human growth hormone therapy derived from algae as a non-invasive alternative to injectable treatments for Growth Hormone Deficiency. Its research spans biology, chemistry, and data with a focus on health and sustainability.
- How much funding has Koyo Sciences raised?
- Koyo Sciences has disclosed $1.3M raised across 1 round.
- Where is Koyo Sciences headquartered?
- Koyo Sciences is headquartered in Brookline, US.